Vancomycin

Infection

CAMC Health SystemSmall moleculePhase 3Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

2 Active assets in the Infection cohort.

Asset / Sponsor	Phase	Rating
SULFAMETHOXAZOLE Radboud University Medical Center	Phase 4	A
Trimethoprim Radboud University Medical Center	Phase 4	A
Ciprofloxacin Radboud University Medical Center	Phase 4	BBB
FILGRASTIM Cellerant Therapeutics	Phase 3	BB
Aztreonam Liverpool Heart and Chest Hospital NHS Foundation Trust	Phase 4	BB

View all 50 →

Same molecule, other indications

Vancomycin is also rated in:

primary sclerosing cholangitisDormant

BB

Indicative ·

71 / 100

methicillin-resistant staphylococcus aureus infectious diseaseDormant

BB

Indicative ·

68 / 100

Febrile Neutropenia (FN)Dormant

BB

Indicative ·

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.